PATENT CLAIM ANALYSIS

Application Number: 15923469
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "497000"]

Abstract:
The present invention relates to pediatric drug formulation. Especially, this invention relates to the manufacturing of granules comprising a core comprising a drug having an unpleasant taste, which may be a primary bile acid, such as for example cholic acid, and a taste-masking coating. The purpose of the invention is to fully mask unpleasant taste of the drug, while ensuring its availability at the duodenum biological site.

Claim (Index 18):
A method of treating a pediatric patient suffering from a deficiency in primary bile acid synthesis comprising administering to said patient: a formulation comprising at least one granule comprising a core, said core comprising at least one unbuffered primary bile acid and at least one binder; and a coating surrounding the core, said coating comprising at least one gastric-fluid-soluble-and-taste-masking compound; said granule presenting a particle size distribution ranging from 90 \u03bcm to 500 \u03bcm wherein the granules larger than 355 \u03bcm is less than the 12% of the total particle size distribution; wherein said formulation further comprises at least one excipient B selected from at least one diluent, at least one disintegrant and at least one lubricant or a combination thereof; or a pharmaceutical composition comprising: at least one granule comprising a core, said core comprising at least one unbuffered primary bile acid and at least one binder; and a coating surrounding the core, said coating comprising at least one gastric-fluid-soluble-and-taste-masking compound; said granule presenting a particle size distribution ranging from 90 \u03bcm to 500 \u03bcm wherein the granules larger than 355 \u03bcm is less than the 12% of the total particle size distribution; or a formulation comprising at least one granule comprising a core, said core comprising at least one unbuffered primary bile acid and at least one binder; and a coating surrounding the core, said coating comprising at least one gastric-fluid-soluble-and-taste-masking compound; said granule presenting a particle size distribution ranging from 90 \u03bcm to 500 \u03bcm wherein the granules larger than 355 \u03bcm is less than the 12% of the total particle size distribution; wherein said formulation further comprises at least one excipient B selected from at least one diluent, at least one disintegrant and at least one lubricant or a combination thereof; wherein said formulation or pharmaceutical composition comprises an effective amount of primary bile acid.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 1.53061
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14384210', '13933323', '12376060', '14889009', '13166770']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.686548671250601
- 35 USC 102 Novelty (BERT): 0.5111511158165223
- Combined Prediction Score: 0.6690089157071932
- Mean Citation Score: 215.20237200000005
- Max Citation Score: 229.28883
- Similarity Product: 129.39323559384763

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test